So we can evaluate project for Italy as well as for a region or even globallyĪché is a 100% Brazilian-owned corporation that has been in activity for 53 years and is one of the three biggest pharmaceutical companies in Brazil. We are willing to explore the possibilities in our core areas of interest for products with a value added, we have a strong sales force in Italy and we have a network of partners around the world growing every day.
Our state of the art facility is a attractive spot for partners who want to cooperate with us for the production of their products, we have three different lines solid oral forms (tablets capsules.), semi solids (cream, gel, ointments.) and liquids (injectables, drops, ampolues.) We are looking for partners in the countries where we are not yet present and that are willing to establish a long term cooperation. We are actively scouting for partners around the world.
#Synergy healthcare alliance full#
Our main products for the export are Vitamin D3 (Colcalciferol), Paracetamol a full line, Paracetamol+ Codeine and clodronic acid, besides we have an interesting pipeline of innovative products in musculoskeletal diseases. Abiogen is Aiming to expand it's business globally through licensees and distributors as well as in creating synergies with partners for our CMO. The key area of interest are Musculoskeletal diseases, pain management and dermatology. After 20 years Abiogen is ranked number 1 by IMS in the field of Vitamin d3 globally: due it's success story in Italy, becoming the reference company in Italy for bone metabolism related pathologies. Besides, Abdi İbrahim has focused its activities on sustainability studies on level A of Global Reporting Initiative (GRI) and published its third Sustainability ReportĪbiogen is privately owned Italian pharmaceutical company, it was established in 1997 after the acquisition of Istituto Gentili by MSD. Abdi İbrahim has taken an important step by signing United Nations Global Principles Agreement in 2010 and given the opportunity to share high standards which it has acquired in the fields of human rights, as well as environmental and social responsibility. Abdi İbrahim has also R&D Centers and production facilities in Kazakhstan and Algeria.
Abdi Ibrahim has an R&D Center, production facility for chemical products, Turkey's largest biotechnological manufacturing facility AbdiBio and hormone production area, ophthalmology production area which will be operational in 2019 and Sterile Injectable & Oncology production facility which will be operational in 2021 in Istanbul Esenyurt production complex. Abdi İbrahim, having the first accredited R&D center in the industry, is a role model with its technological equipment and architecture as well as R&D processes in healing the future. The company also comes to the fore with its marketing and sales team, which is the largest in the industry.
Today, Abdi İbrahim, which operates in 12 countries outside Turkey, exports to more than 60 countries ranging from Canada to European Union member states, from North Africa to Asia and creates the highest employment with nearly 4.500 qualified employees in the Turkish pharmaceutical industry. With a powerful vision, dynamic structure and contemporary outlook, Abdi İbrahim has been the leader of Turkey’s Pharmaceutical Industry since 2002. Abdi İbrahim has the largest product portfolio in the sector, exceeding 200 brands and more than 450 products by developing its own products as well as working with 30 licensors. Abdi İbrahim, Turkish pharmaceutical industry leader, was founded in 1912 in Küçükmustafapaşa, Istanbul at a small pharmacy, by Pharmacist Abdi İbrahim Bey who had started the “healing” journey.
0 kommentar(er)
